Current Challenges in Pediatric Pulmonary Hypertension

 

 Buy Article Permissions and Reprints

Abstract

Pulmonary arterial hypertension (PAH) in the pediatric population is associated with a variety of underlying diseases and causes, significantly morbidity and mortality. In the majority of patients, PAH in children is idiopathic or associated with congenital heart disease (CHD), with pulmonary hypertension (PH) associated with connective tissue disease, a rare cause in children. Classification of pediatric PH has generally followed the WHO classification, but recognition of the importance of fetal origins of PH and developmental abnormalities have led to the formation of a new pediatric-specific classification. Incidence data from the Netherlands has revealed an annual incidence and point prevalence of 0.7 and 4.4 for idiopathic PAH and 2.2 and 15.6 for associated pulmonary arterial hypertension-CHD cases per million children. Although the treatment with new selective pulmonary vasodilators offers hemodynamic and functional improvement in pediatric populations, the treatments in children largely depend on results from evidence-based adult studies and experience of clinicians treating children. A recent randomized clinical trial of sildenafil and its long-term extension has led to disparate recommendations in the United States and Europe.

• References

• 1 Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012; 125 (1) 113-122
  CrossrefPubMedGoogle Scholar
• 2 Berger RM, Beghetti M, Humpl T , et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012; 379 (9815) 537-546
  CrossrefPubMedGoogle Scholar
• 3 Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009; 95 (4) 312-317
  CrossrefPubMedGoogle Scholar
• 4 Fraisse A, Jais X, Schleich JM , et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 2010; 103 (2) 66-74
  CrossrefPubMedGoogle Scholar
• 5 D'Alonzo GE, Barst RJ, Ayres SM , et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115 (5) 343-349
  CrossrefPubMedGoogle Scholar
• 6 Simonneau G, Robbins IM, Beghetti M , et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1, Suppl): S43-S54
  CrossrefPubMedGoogle Scholar
• 7 McLaughlin VV, Archer SL, Badesch DB , et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53 (17) 1573-1619
  CrossrefPubMedGoogle Scholar
• 8 Cerro MJ, Abman S, Diaz G , et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ 2011; 1 (2) 286-298
  CrossrefPubMedGoogle Scholar
• 9 van Albada ME, Berger RM. Pulmonary arterial hypertension in congenital cardiac disease—the need for refinement of the Evian-Venice classification. Cardiol Young 2008; 18 (1) 10-17
  PubMedGoogle Scholar
• 10 Schulze-Neick I, Beghetti M. Classifying pulmonary hypertension in the setting of the congenitally malformed heart—cleaning up a dog's dinner. Cardiol Young 2008; 18 (1) 22-25
  CrossrefPubMedGoogle Scholar
• 11 Badesch DB, Champion HC, Sanchez MA , et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1, Suppl): S55-S66
  CrossrefPubMedGoogle Scholar
• 12 Beghetti M, Galiè N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53 (9) 733-740
  CrossrefPubMedGoogle Scholar
• 13 Hassoun PM, Mouthon L, Barberà JA , et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54 (1, Suppl): S10-S19
  CrossrefPubMedGoogle Scholar
• 14 Humbert M, Morrell NW, Archer SL , et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12, Suppl S): 13S-24S
  CrossrefPubMedGoogle Scholar
• 15 Rabinovitch M. Pathobiology of pulmonary hypertension. Annu Rev Pathol 2007; 2: 369-399
  CrossrefPubMedGoogle Scholar
• 16 Diller GP, Thum T, Wilkins MR, Wharton J. Endothelial progenitor cells in pulmonary arterial hypertension. Trends Cardiovasc Med 2010; 20 (1) 22-29
  CrossrefPubMedGoogle Scholar
• 17 Diller GP, van Eijl S, Okonko DO , et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 2008; 117 (23) 3020-3030
  CrossrefPubMedGoogle Scholar
• 18 Lavoie JR, Stewart DJ. Genetically modified endothelial progenitor cells in the therapy of cardiovascular disease and pulmonary hypertension. Curr Vasc Pharmacol 2012; 10 (3) 289-299
  CrossrefPubMedGoogle Scholar
• 19 Smadja DM, Mauge L, Gaussem P , et al. Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. Angiogenesis 2011; 14 (1) 17-27
  CrossrefPubMedGoogle Scholar
• 20 Stewart DJ, Zhao YD, Courtman DW. Cell therapy for pulmonary hypertension: what is the true potential of endothelial progenitor cells?. Circulation 2004; 109: 172-173
  CrossrefPubMedGoogle Scholar
• 21 Zhu JH, Wang XX, Zhang FR , et al. Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study. Pediatr Transplant 2008; 12 (6) 650-655
  CrossrefPubMedGoogle Scholar
• 22 Lama VN, Phan SH. The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. Proc Am Thorac Soc 2006; 3 (4) 373-376
  CrossrefPubMedGoogle Scholar
• 23 Moeller A, Gilpin SE, Ask K , et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179 (7) 588-594
  CrossrefPubMedGoogle Scholar
• 24 Yeager ME, Nguyen CM, Belchenko DD , et al. Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension. Chest 2012; 141 (4) 944-952
  CrossrefPubMedGoogle Scholar
• 25 Yeager ME, Nguyen CM, Belchenko DD , et al. Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J 2012; 39 (1) 104-111
  CrossrefPubMedGoogle Scholar
• 26 van Loon RL, Roofthooft MT, Hillege HL , et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011; 124 (16) 1755-1764
  CrossrefPubMedGoogle Scholar
• 27 Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 2010; 96 (17) 1401-1406
  CrossrefPubMedGoogle Scholar
• 28 Sandoval J, Bauerle O, Gomez A, Palomar A, Martínez Guerra ML, Furuya ME. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol 1995; 25 (2) 466-474
  CrossrefPubMedGoogle Scholar
• 29 Lammers AE, Adatia I, Cerro MJ , et al. Functional classification of pulmonary hypertension in children: Report from the PVRI pediatric taskforce, Panama 2011. Pulm Circ 2011; 1 (2) 280-285
  CrossrefPubMedGoogle Scholar
• 30 van Loon RL, Roofthooft MT, Delhaas T , et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. Am J Cardiol 2010; 106 (1) 117-124
  CrossrefPubMedGoogle Scholar
• 31 Bernus A, Wagner BD, Accurso F, Doran A, Kaess H, Ivy DD. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 2009; 135 (3) 745-751
  CrossrefPubMedGoogle Scholar
• 32 Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol 2009; 135 (1) 21-26
  CrossrefPubMedGoogle Scholar
• 33 Takatsuki S, Wagner BD, Ivy DD. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit Heart Dis 2012; 7 (3) 259-267
  CrossrefPubMedGoogle Scholar
• 34 Van Albada ME, Loot FG, Fokkema R, Roofthooft MT, Berger RM. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res 2008; 63 (3) 321-327
  CrossrefPubMedGoogle Scholar
• 35 Takatsuki S, Ivy DD, Nuss R. Correlation of N-terminal fragment of B-type natriuretic peptide levels with clinical, laboratory, and echocardiographic abnormalities in children with sickle cell disease. J Pediatr 2012; 160 (3) 428-433 , e1
  PubMedGoogle Scholar
• 36 Yeager ME, Colvin KL, Everett AD, Stenmark KR, Ivy DD. Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension. Proteomics Clin Appl 2012; 6 (5-6) 257-267
  CrossrefPubMedGoogle Scholar
• 37 Forfia PR, Fisher MR, Mathai SC , et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006; 174 (9) 1034-1041
  CrossrefPubMedGoogle Scholar
• 38 Dyer KL, Pauliks LB, Das B , et al. Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension. J Am Soc Echocardiogr 2006; 19 (1) 21-27
  CrossrefPubMedGoogle Scholar
• 39 Lammers AE, Haworth SG, Riley G, Maslin K, Diller GP, Marek J. Value of tissue Doppler echocardiography in children with pulmonary hypertension. J Am Soc Echocardiogr 2012; 25 (5) 504-510
  CrossrefPubMedGoogle Scholar
• 40 Sachdev V, Machado RF, Shizukuda Y , et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol 2007; 49 (4) 472-479
  CrossrefPubMedGoogle Scholar
• 41 Takatsuki S, Nakayama T, Jone PN , et al. Tissue Doppler imaging predicts adverse outcome in children with idiopathic pulmonary arterial hypertension. J Pediatr 2012; 161 (6) 1126-1131
  PubMedGoogle Scholar
• 42 Alkon J, Humpl T, Manlhiot C, McCrindle BW, Reyes JT, Friedberg MK. Usefulness of the right ventricular systolic to diastolic duration ratio to predict functional capacity and survival in children with pulmonary arterial hypertension. Am J Cardiol 2010; 106 (3) 430-436
  CrossrefPubMedGoogle Scholar
• 43 Douwes JM, van Loon RL, Hoendermis ES , et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J 2011; 32 (24) 3137-3146
  CrossrefPubMedGoogle Scholar
• 44 Dyer K, Lanning C, Das B , et al. Noninvasive Doppler tissue measurement of pulmonary artery compliance in children with pulmonary hypertension. J Am Soc Echocardiogr 2006; 19 (4) 403-412
  PubMedGoogle Scholar
• 45 Gan CT, Lankhaar JW, Westerhof N , et al. Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest 2007; 132 (6) 1906-1912
  CrossrefPubMedGoogle Scholar
• 46 Lankhaar JW, Westerhof N, Faes TJ , et al. Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. Eur Heart J 2008; 29 (13) 1688-1695
  CrossrefPubMedGoogle Scholar
• 47 Lankhaar JW, Westerhof N, Faes TJ , et al. Quantification of right ventricular afterload in patients with and without pulmonary hypertension. Am J Physiol Heart Circ Physiol 2006; 291 (4) H1731-H1737
  CrossrefPubMedGoogle Scholar
• 48 Weinberg CE, Hertzberg JR, Ivy DD , et al. Extraction of pulmonary vascular compliance, pulmonary vascular resistance, and right ventricular work from single-pressure and Doppler flow measurements in children with pulmonary hypertension: a new method for evaluating reactivity: in vitro and clinical studies. Circulation 2004; 110 (17) 2609-2617
  CrossrefPubMedGoogle Scholar
• 49 Mahapatra S, Nishimura RA, Oh JK, McGoon MD. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr 2006; 19 (8) 1045-1050
  PubMedGoogle Scholar
• 50 Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 2006; 47 (4) 799-803
  CrossrefPubMedGoogle Scholar
• 51 Sajan I, Manlhiot C, Reyes J, McCrindle BW, Humpl T, Friedberg MK. Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival. Am Heart J 2011; 162 (3) 562-568
  CrossrefPubMedGoogle Scholar
• 52 Friedberg MK, Feinstein JA, Rosenthal DN. Noninvasive assessment of pulmonary arterial capacitance by echocardiography. J Am Soc Echocardiogr 2007; 20 (2) 186-190
  PubMedGoogle Scholar
• 53 Hunter KS, Lee PF, Lanning CJ , et al. Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension. Am Heart J 2008; 155 (1) 166-174
  CrossrefPubMedGoogle Scholar
• 54 Rosenzweig EB, Feinstein JA, Humpl T, Ivy DD. Pulmonary arterial hypertension in children: Diagnostic work-up and challenges. Prog Pediatr Cardiol 2009; 27 (1) 4-11
  PubMedGoogle Scholar
• 55 Das BB, Wolfe RR, Chan KC, Larsen GL, Reeves JT, Ivy D. High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude. Arch Pediatr Adolesc Med 2004; 158 (12) 1170-1176
  CrossrefPubMedGoogle Scholar
• 56 Condino AA, Ivy DD, O'Connor JA , et al. Portopulmonary hypertension in pediatric patients. J Pediatr 2005; 147 (1) 20-26
  CrossrefPubMedGoogle Scholar
• 57 Whitworth JR, Ivy DD, Gralla J, Narkewicz MR, Sokol RJ. Pulmonary vascular complications in asymptomatic children with portal hypertension. J Pediatr Gastroenterol Nutr 2009; 49 (5) 607-612
  CrossrefPubMedGoogle Scholar
• 58 Tissot C, Ivy DD, Beghetti M. Medical therapy for pediatric pulmonary arterial hypertension. J Pediatr 2010; 157 (4) 528-532
  CrossrefPubMedGoogle Scholar
• 59 Barst R. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?. Int J Clin Pract Suppl 2010; 64 (168) 23-32
  CrossrefPubMedGoogle Scholar
• 60 Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99 (9) 1197-1208
  CrossrefPubMedGoogle Scholar
• 61 Barst RJ, Rubin LJ, Long WA , et al; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334 (5) 296-301
  CrossrefPubMedGoogle Scholar
• 62 Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121 (6) 409-415
  CrossrefPubMedGoogle Scholar
• 63 Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol 2007; 99 (5) 696-698
  CrossrefPubMedGoogle Scholar
• 64 Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 2004; 93 (7) 943-946
  CrossrefPubMedGoogle Scholar
• 65 Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. Heart 2007; 93 (6) 739-743
  CrossrefPubMedGoogle Scholar
• 66 Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99 (14) 1858-1865
  CrossrefPubMedGoogle Scholar
• 67 Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110 (6) 660-665
  CrossrefPubMedGoogle Scholar
• 68 Ivy DD. Prostacyclin in the intensive care setting. Pediatr Crit Care Med 2010; 11 (2, Suppl): S41-S45
  CrossrefPubMedGoogle Scholar
• 69 Barst RJ, Galie N, Naeije R , et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28 (6) 1195-1203
  CrossrefPubMedGoogle Scholar
• 70 Ivy DD, Rosenzweig EB, Lemarié JC, Brand M, Rosenberg D, Barst RJ. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 2010; 106 (9) 1332-1338
  CrossrefPubMedGoogle Scholar
• 71 Centers for Disease Control and Prevention (CDC). Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension—seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 2007; 56 (8) 170-172
  PubMedGoogle Scholar
• 72 Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL ; Scientific Leadership Council of the Pulmonary Hypertension Association. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008; (160) 5-9
  PubMedGoogle Scholar
• 73 Ivy DD, Calderbank M, Wagner BD , et al. Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension. Infect Control Hosp Epidemiol 2009; 30 (9) 823-829
  CrossrefPubMedGoogle Scholar
• 74 Rich JD, Glassner C, Wade M , et al. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. Chest 2012; 141 (1) 36-42
  CrossrefPubMedGoogle Scholar
• 75 Levy M, Celermajer DS, Bourges-Petit E, Del Cerro MJ, Bajolle F, Bonnet D. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr 2011; 158 (4) 584-588
  PubMedGoogle Scholar
• 76 Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006; 48 (7) 1433-1437
  CrossrefPubMedGoogle Scholar
• 77 McLaughlin VV, Benza RL, Rubin LJ , et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55 (18) 1915-1922
  CrossrefPubMedGoogle Scholar
• 78 Krishnan U, Takatsuki S, Ivy DD , et al. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. Am J Cardiol 2012; 110 (11) 1704-1709
  CrossrefPubMedGoogle Scholar
• 79 Beghetti M, Berner M, Rimensberger PC. Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion. Heart 2001; 86 (3) E10
  CrossrefPubMedGoogle Scholar
• 80 Hoeper MM, Schwarze M, Ehlerding S , et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342 (25) 1866-1870
  CrossrefPubMedGoogle Scholar
• 81 Ivy DD, Doran AK, Smith KJ , et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51 (2) 161-169
  CrossrefPubMedGoogle Scholar
• 82 Limsuwan A, Khosithseth A, Wanichkul S, Khowsathit P. Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease. Catheter Cardiovasc Interv 2009; 73 (1) 98-104
  CrossrefPubMedGoogle Scholar
• 83 Limsuwan A, Wanitkul S, Khosithset A, Attanavanich S, Samankatiwat P. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol 2008; 129 (3) 333-338
  CrossrefPubMedGoogle Scholar
• 84 Tissot C, Beghetti M. Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag 2009; 5 (1) 325-331
  PubMedGoogle Scholar
• 85 Rimensberger PC, Spahr-Schopfer I, Berner M , et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001; 103 (4) 544-548
  CrossrefPubMedGoogle Scholar
• 86 Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 2009; 361 (19) 1864-1871
  CrossrefPubMedGoogle Scholar
• 87 Michelakis E, Tymchak W, Archer S. Sildenafil: from the bench to the bedside. CMAJ 2000; 163 (9) 1171-1175
  PubMedGoogle Scholar
• 88 Galiè N, Brundage BH, Ghofrani HA , et al; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119 (22) 2894-2903
  CrossrefPubMedGoogle Scholar
• 89 Galiè N, Ghofrani HA, Torbicki A , et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353 (20) 2148-2157
  CrossrefPubMedGoogle Scholar
• 90 Ivy DD, Kinsella JP, Ziegler JW, Abman SH. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 1998; 115 (4) 875-882
  CrossrefPubMedGoogle Scholar
• 91 Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91 (1) 307-310
  CrossrefPubMedGoogle Scholar
• 92 Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006; 174 (9) 1042-1047
  CrossrefPubMedGoogle Scholar
• 93 Atz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 2002; 124 (3) 628-629
  CrossrefPubMedGoogle Scholar
• 94 Ghofrani HA, Wiedemann R, Rose F , et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360 (9337) 895-900
  CrossrefPubMedGoogle Scholar
• 95 Ciliberti P, Giardini A. Impact of oral chronic administration of sildenafil in children and young adults after the Fontan operation. Future Cardiol 2011; 7 (5) 609-612
  CrossrefPubMedGoogle Scholar
• 96 Ciliberti P, Schulze-Neick I, Giardini A. Modulation of pulmonary vascular resistance as a target for therapeutic interventions in Fontan patients: focus on phosphodiesterase inhibitors. Future Cardiol 2012; 8 (2) 271-284
  CrossrefPubMedGoogle Scholar
• 97 Do P, Randhawa I, Chin T, Parsapour K, Nussbaum E. Successful management of plastic bronchitis in a child post Fontan: case report and literature review. Lung 2012; 190 (4) 463-468
  CrossrefPubMedGoogle Scholar
• 98 Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008; 29 (13) 1681-1687
  CrossrefPubMedGoogle Scholar
• 99 Goldberg DJ, French B, Szwast AL , et al. Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. Pediatr Cardiol 2012; 33 (5) 689-696
  CrossrefPubMedGoogle Scholar
• 100 Hager A, Fratz S, Hess J. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2009; 30 (4) 507-508 , author reply 508
  PubMedGoogle Scholar
• 101 Haseyama K, Satomi G, Yasukochi S, Matsui H, Harada Y, Uchita S. Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 2006; 132 (5) 1232-1233
  CrossrefPubMedGoogle Scholar
• 102 Llamas JP, Szkutnik M, Fiszer R, Białkowski J. Treatment of elevated pulmonary artery pressure in a child after Glenn procedure: transcatheter closure of pulmonary artery banding with subsequent sildenafil therapy. Kardiol Pol 2012; 70 (2) 201-203
  PubMedGoogle Scholar
• 103 Morchi GS, Ivy DD, Duster MC, Claussen L, Chan KC, Kay J. Sildenafil Increases Systemic Saturation and Reduces Pulmonary Artery Pressure in Patients with Failing Fontan Physiology. Congenit Heart Dis 2009; 4 (2) 107-111
  CrossrefPubMedGoogle Scholar
• 104 Reinhardt Z, Uzun O, Bhole V , et al. Sildenafil in the management of the failing Fontan circulation. Cardiol Young 2010; 20 (5) 522-525
  CrossrefPubMedGoogle Scholar
• 105 Shabanian R, Shahbaznejad L, Razaghian A , et al. Sildenafil and Ventriculo-Arterial Coupling in Fontan-Palliated Patients: A Noninvasive Echocardiographic Assessment. Pediatr Cardiol 2013; 34 (1) 129-134
  CrossrefPubMedGoogle Scholar
• 106 Uzun O, Wong JK, Bhole V, Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg 2006; 82 (6) e39-e40
  CrossrefPubMedGoogle Scholar
• 107 Goldberg DJ, French B, McBride MG , et al. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation 2011; 123 (11) 1185-1193
  CrossrefPubMedGoogle Scholar
• 108 Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111 (24) 3274-3280
  CrossrefPubMedGoogle Scholar
• 109 Karatza AA, Bush A, Magee AG. Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 2005; 100 (2) 267-273
  CrossrefPubMedGoogle Scholar
• 110 Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009; 154 (3) 379-384 , e1–e2
  PubMedGoogle Scholar
• 111 Satoh T, Saji T, Watanabe H , et al. A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension. Circ J 2011; 75 (3) 677-682
  CrossrefPubMedGoogle Scholar
• 112 Barst RJ, Ivy DD, Gaitan G , et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125 (2) 324-334
  CrossrefPubMedGoogle Scholar
• 113 Barst R, Layton G, Konourina I, Richardson H, Beghetti M, Ivy D. STARTS-2: Long-Term Survival With Oral Sildenafil Monotherapy in Treatment-Naive Patients With Pediatric Pulmonary Arterial Hypertension. Eur Heart J 2012; 33: 979
  PubMedGoogle Scholar
• 114 Steinhorn RH, Kinsella JP, Pierce C , et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009; 155 (6) 841-847 , e1
  CrossrefPubMedGoogle Scholar
• 115 Fraisse A, Butrous G, Taylor MB, Oakes M, Dilleen M, Wessel DL. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med 2011; 37 (3) 502-509
  CrossrefPubMedGoogle Scholar
• 116 Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 2012; 33 (5) 683-688
  CrossrefPubMedGoogle Scholar
• 117 Pettit RS, Johnson CE, Caruthers RL. Stability of an extemporaneously prepared tadalafil suspension. Am J Health Syst Pharm 2012; 69 (7) 592-594
  CrossrefPubMedGoogle Scholar
• 118 Channick RN, Simonneau G, Sitbon O , et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358 (9288) 1119-1123
  CrossrefPubMedGoogle Scholar
• 119 Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant 2005; 24 (8) 1174-1176
  CrossrefPubMedGoogle Scholar
• 120 Barst RJ, Ivy D, Dingemanse J , et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73 (4) 372-382
  CrossrefPubMedGoogle Scholar
• 121 Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr Vasc Pharmacol 2009; 7 (2) 225-233
  CrossrefPubMedGoogle Scholar
• 122 Beghetti M, Hoeper MM, Kiely DG , et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 2008; 64 (2) 200-204
  CrossrefPubMedGoogle Scholar
• 123 D'Alto M, Romeo E, Argiento P , et al. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome. Int J Cardiol 2013; 164 (3) 323-326
  CrossrefPubMedGoogle Scholar
• 124 Duffels MG, Vis JC, van Loon RL , et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option?. Int J Cardiol 2009; 134 (3) 378-383
  CrossrefPubMedGoogle Scholar
• 125 Hislop AA, Moledina S, Foster H, Schulze-Neick I, Haworth SG. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J 2011; 38 (1) 70-77
  CrossrefPubMedGoogle Scholar
• 126 Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92 (5) 664-670
  CrossrefPubMedGoogle Scholar
• 127 Rosenzweig EB, Ivy DD, Widlitz A , et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46 (4) 697-704
  CrossrefPubMedGoogle Scholar
• 128 Taguchi M, Ichida F, Hirono K , et al. Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. Drug Metab Pharmacokinet 2011; 26 (3) 280-287
  CrossrefPubMedGoogle Scholar
• 129 van Loon RL, Hoendermis ES, Duffels MG , et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?. Am Heart J 2007; 154 (4) 776-782
  CrossrefPubMedGoogle Scholar
• 130 Votava-Smith JK, Perens GS, Alejos JC. Bosentan for increased pulmonary vascular resistance in a patient with single ventricle physiology and a bidirectional Glenn shunt. Pediatr Cardiol 2007; 28 (4) 314-316
  CrossrefPubMedGoogle Scholar
• 131 Galiè N, Beghetti M, Gatzoulis MA , et al; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114 (1) 48-54
  CrossrefPubMedGoogle Scholar
• 132 Beghetti M, Haworth SG, Bonnet D , et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009; 68 (6) 948-955
  CrossrefPubMedGoogle Scholar
• 133 Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Am J Cardiol 2011; 108 (2) 302-307
  CrossrefPubMedGoogle Scholar
• 134 Oudiz RJ, Galiè N, Olschewski H , et al; ARIES Study Group. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (21) 1971-1981
  CrossrefPubMedGoogle Scholar
• 135 Galiè N, Olschewski H, Oudiz RJ , et al; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117 (23) 3010-3019
  CrossrefPubMedGoogle Scholar
• 136 Galié N, Badesch D, Oudiz R , et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46 (3) 529-535
  CrossrefPubMedGoogle Scholar
• 137 Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol 2013; 48 (1) 27-34
  CrossrefPubMedGoogle Scholar
• 138 Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenzweig EB. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol 2011; 107 (9) 1381-1385
  CrossrefPubMedGoogle Scholar
• 139 Humbert M, Barst RJ, Robbins IM , et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24 (3) 353-359
  CrossrefPubMedGoogle Scholar
• 140 Simonneau G, Rubin LJ, Galiè N , et al; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149 (8) 521-530
  CrossrefPubMedGoogle Scholar
• 141 Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26 (5) 858-863
  CrossrefPubMedGoogle Scholar
• 142 Hanna B, Conrad C. Lung transplantation for pediatric pulmonary hypertension. Prog Pediatr Cardiol 2009; 27: 49-55
  CrossrefPubMedGoogle Scholar
• 143 Lammers AE, Burch M, Benden C , et al. Lung transplantation in children with idiopathic pulmonary arterial hypertension. Pediatr Pulmonol 2010; 45 (3) 263-269
  PubMedGoogle Scholar
• 144 Schaellibaum G, Lammers AE, Faro A , et al. Bilateral lung transplantation for pediatric idiopathic pulmonary arterial hypertension: a multi-center experience. Pediatr Pulmonol 2011; 46 (11) 1121-1127
  CrossrefPubMedGoogle Scholar
• 145 Goldstein BS, Sweet SC, Mao J, Huddleston CB, Grady RM. Lung transplantation in children with idiopathic pulmonary arterial hypertension: an 18-year experience. J Heart Lung Transplant 2011; 30 (10) 1148-1152
  CrossrefPubMedGoogle Scholar
• 146 Aurora P, Edwards LB, Kucheryavaya AY , et al. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric lung and heart-lung transplantation report—2010. J Heart Lung Transplant 2010; 29 (10) 1129-1141
  CrossrefPubMedGoogle Scholar